Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals Inc (NQ: PHAT )

10.09 -0.01 (-0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,113,582
Open 9.700
Bid (Size) 10.20 (1)
Ask (Size) 10.70 (1)
Prev. Close 10.10
Today's Range 9.680 - 11.15
52wk Range 6.065 - 17.02
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
PHAT stock results show that Phathom Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+10.03%
+10.03%
1 Month
-16.27%
-16.27%
3 Month
+44.66%
+44.66%
6 Month
+28.37%
+28.37%
1 Year
-18.83%
-18.83%

More News

Read More
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Preview: Phathom Pharmaceuticals's Earnings
Via Benzinga
Recap: Phathom Pharmaceuticals Q3 Earnings
Via Benzinga
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
From Phathom Pharmaceuticals
Via GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Via Benzinga
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Via Benzinga
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
What's Going On With Phathom Pharmaceuticals Stock?
Via Benzinga
Exposures Product Safety
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.